Interim analysis of COVID-19 vaccine effectiveness against
Severe Acute Respiratory Infection

V 2021

Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection

BACCI, Sabrina, Nathalie NICOLAY, Ester KISSLING, Anthony NARDONE, Angie ROSE et. al.

Basic information

Original name

Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection

Authors

BACCI, Sabrina (guarantor), Nathalie NICOLAY, Ester KISSLING, Anthony NARDONE, Angie ROSE, Marta VALENCIANO and Lenka SOUČKOVÁ (203 Czech Republic, belonging to the institution)

Edition

NA. Stockholm, 15 pp. NA, 2021

Publisher

ECDC European Centre for Disease Prevention and Control

Other information

Language

English

Type of outcome

Výzkumná zpráva

Field of Study

30230 Other clinical medicine subjects

Country of publisher

Sweden

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

COVID-19

RIV identification code

RIV/00216224:14110/21:00123713

Organization unit

Faculty of Medicine

Keywords (in Czech)

COVID-19 vakcína; efektivita; Akutní respirační infekce

Keywords in English

COVID-19 vaccine; effectiveness; Acute Respiratory Infection

Abstract

V originále

This document reports the first interim pooled estimates from the ECDC study of COVID-19 vaccine effectiveness (VE), conducted through the implementation of a multi-country approach using the Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratoryconfirmed with SARS-CoV-2, version 1.0 [1].Interim pooled estimates of COVID-19 VE were calculated for all COVID-19 vaccines deployed, including the COVID-19 mRNA vaccine Comirnaty (Pfizer/BioNTech), among hospitalised individuals aged 65 years and older with SARI due to laboratory-confirmed SARS-CoV-2, across EU/EEA participating countries. The study is currently ongoing and interim analyses will be conducted on a regular basis, with results updated as relevant. Pooled estimates are from patients recruited across several hospital study sites in the EU/EEA. These interim estimates mainly cover the pre-Delta period, adding further evidence to the existing literature on COVID-19 VE during this time. While VE estimates are important to inform vaccine recommendations, it is also important to ensure that robust methods were used to produce these estimates. Hence, this document presents a detailed description of both the methods used and the characteristics of the cases and controls enrolled in the study. For more details regarding the methods of the study, reference should be made to the core ECDC protocol [1].

Links

90128, large research infrastructures

Name: CZECRIN III

Citovat

BACCI, Sabrina, Nathalie NICOLAY, Ester KISSLING, Anthony NARDONE, Angie ROSE, Marta VALENCIANO and Lenka SOUČKOVÁ. Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection. NA. Stockholm: ECDC European Centre for Disease Prevention and Control, 2021, 15 pp. NA.

@misc{1820851,
   author = {Bacci, Sabrina and Nicolay, Nathalie and Kissling, Ester and Nardone, Anthony and Rose, Angie and Valenciano, Marta and Součková, Lenka},
   address = {Stockholm},
   edition = {NA},
   keywords = {COVID-19 vaccine; effectiveness; Acute Respiratory Infection},
   language = {eng},
   location = {Stockholm},
   publisher = {ECDC European Centre for Disease Prevention and Control},
   title = {Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection},
   url = {https://www.ecdc.europa.eu/sites/default/files/documents/TRP-20211004-1860_0.pdf},
   year = {2021}
}

TY  - GEN
ID  - 1820851
AU  - Bacci, Sabrina - Nicolay, Nathalie - Kissling, Ester - Nardone, Anthony - Rose, Angie - Valenciano, Marta - Součková, Lenka
PY  - 2021
TI  - Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection
VL  - NA
PB  - ECDC European Centre for Disease Prevention and Control
CY  - Stockholm
KW  - COVID-19 vaccine
KW  - effectiveness
KW  - Acute Respiratory Infection
UR  - https://www.ecdc.europa.eu/sites/default/files/documents/TRP-20211004-1860_0.pdf
N2  - This document reports the first interim pooled estimates from the ECDC study of COVID-19 vaccine effectiveness (VE), conducted through the implementation of a multi-country approach using the Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratoryconfirmed with SARS-CoV-2, version 1.0 [1].Interim pooled estimates of COVID-19 VE were calculated for all COVID-19 vaccines deployed, including the COVID-19 mRNA vaccine Comirnaty (Pfizer/BioNTech), among hospitalised individuals aged 65 years and older with SARI due to laboratory-confirmed SARS-CoV-2, across EU/EEA participating countries. The study is currently ongoing and interim analyses will be conducted on a regular basis, with results updated as relevant. Pooled estimates are from patients recruited across several hospital study sites in the EU/EEA. These interim estimates mainly cover the pre-Delta period, adding further evidence to the existing literature on COVID-19 VE during this time. While VE estimates are important to inform vaccine recommendations, it is also important to ensure that robust methods were used to produce these estimates. Hence, this document presents a detailed description of both the methods used and the characteristics of the cases and controls enrolled in the study. For more details regarding the methods of the study, reference should be made to the core ECDC protocol [1].
ER  -

BACCI, Sabrina, Nathalie NICOLAY, Ester KISSLING, Anthony NARDONE, Angie ROSE, Marta VALENCIANO and Lenka SOUČKOVÁ. \textit{Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection}. NA. Stockholm: ECDC European Centre for Disease Prevention and Control, 2021, 15 pp. NA.

Detailed Information on Publication Record